Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Rises By 426.4%

BiomX Inc. (NYSEAMERICAN:PHGE) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 270,744 shares, an increase of 426.4% from the January 15th total of 51,433 shares. Currently, 17.5% of the shares of the company are sold short. Based on an average daily volume of 5,798,754 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily volume of 5,798,754 shares, the days-to-cover ratio is presently 0.0 days. Currently, 17.5% of the shares of the company are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BiomX stock. Citadel Advisors LLC acquired a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned approximately 0.61% of BiomX as of its most recent SEC filing. Hedge funds and other institutional investors own 40.57% of the company’s stock.

BiomX Trading Up 44.4%

Shares of PHGE opened at $6.54 on Wednesday. BiomX has a 12 month low of $1.50 and a 12 month high of $22.06. The firm has a fifty day simple moving average of $3.27 and a 200 day simple moving average of $7.07. The stock has a market capitalization of $10.40 million, a price-to-earnings ratio of -0.26 and a beta of 1.66.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating on shares of BiomX in a research report on Tuesday, November 25th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, BiomX currently has an average rating of “Buy” and an average price target of $26.00.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.